

Product datasheet for TL313363V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Desmocollin 3 (DSC3) Human shRNA Lentiviral Particle (Locus ID 1825)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Desmocollin 3 (DSC3) Human shRNA Lentiviral Particle (Locus ID 1825)

Locus ID: 1825

Synonyms: CDHF3; DSC; DSC1; DSC2; DSC4; HT-CP

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: DSC3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001941, NM 024423, NM 024423.1, NM 024423.2, NM 024423.3, NM 001941.1,

NM 001941.2, NM 001941.3, NM 001941.4, NM 001941.5

UniProt ID: Q14574

Summary: The protein encoded by this gene is a calcium-dependent glycoprotein that is a member of

the desmocollin subfamily of the cadherin superfamily. These desmosomal family members, along with the desmogleins, are found primarily in epithelial cells where they constitute the adhesive proteins of the desmosome cell-cell junction and are required for cell adhesion and desmosome formation. The desmosomal family members are arranged in two clusters on chromosome 18, occupying less than 650 kb combined. Mutations in this gene are a cause of hypotrichosis and recurrent skin vesicles disorder. The protein can act as an autoantigen in

Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq,

pemphigus diseases, and it is also considered to be a biomarker for some cancers.

Apr 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).